The Medical Letter on Drugs and Therapeutics
Eloctate for Hemophilia A
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 11/10/2015: In the table, Nuwiq's indications, half-life, and cost have been revised.

The FDA has approved Eloctate (Biogen), a recombinant factor VIII Fc fusion protein with an extended half-life, for use in adults and children with hemophilia A. Eloctate is indicated for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. It is the first antihemophilic factor VIII Fc fusion protein to be approved for hemophilia A.

FACTOR VIII REPLACEMENT THERAPY — Regular injections of plasma-derived or recombinant factor VIII products are the standard of care for prevention of bleeding and joint destruction in patients with hemophilia A. Plasma-derived products have been associated with transmission of blood-borne viruses such as HIV, hepatitis B, and hepatitis C, but use of viral inactivation methods has eliminated most of this risk. Plasma-derived and recombinant factor VIII products are ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Eloctate for Hemophilia A
Article code: 1479d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian